  |
 | Up a level |
Bondarenko, I. and Sezer, A. and Kilickap, S. and Gümüs, M. and Özgüroğlu, M. and Gogishvili, M. and He, X. and Gullo, G. and Rietschel, P. and Quek, R.G. (2022) Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation. Annals of Oncology, Vol.33 (Supp.2). S84-S85. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
Sriuranpong, V. and Altundag, O. and Clingan, P. and Rizvi, N. and Aren Frontera, O. and Sezer, A. and Paydas, S. and Shavdia, M. and Bondarenko, I. and Gladkov, O. and Lee, S. and Li, S. and Snodgrass, P. and Rietschel, P. (2018) EMPOWER-lung 1: A randomized, open-label, multi-national, phase III trial of cemiplimab, a human PD-1 monoclonal antibody, versus chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 50%. Annals of Oncology, Vol.29 (Sup.10). mdy487.039. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
